Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biomarkers in Cancer / / edited by Victor R. Preedy, Vinood B. Patel
| Biomarkers in Cancer / / edited by Victor R. Preedy, Vinood B. Patel |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2015 |
| Descrizione fisica | 1 online resource (180 illus., 134 illus. in color. eReference.) |
| Disciplina | 616.9940756 |
| Collana | Biomarkers in Disease: Methods, Discoveries and Applications |
| Soggetto topico |
Cancer - Research
Oncology Pharmacology Cancer Research Pharmacology/Toxicology |
| ISBN | 94-007-7681-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Series Preface -- Contents -- About the Editors -- Editorial Advisors -- Contributors -- Part I: General Aspects: Techniques and Overviews -- 1 OMICS for Tumor Biomarker Research -- Key Facts of OMICS Sciences -- Definitions of Words and Terms -- Introduction: A Role of OMICS in Cancer Biomarker Research -- An Analysis Pathway for Multiplex Biomarker Panels -- Transcriptome Profiling Approaches and Multiplexed Panels Based on mRNA Levels -- Proteomics: From MALDI-TOF Through Shotgun Techniques to Targeted Approach -- Metabolomics: A Promising New Direction for Biomarker Discovery -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Conclusion -- Summary Points -- References -- 2 Circulating Tumor Cells as Biomarkers in Cancer -- Key Facts About Circulating Tumor Cells (CTCs) -- Definition of Words and Terms -- Introduction to Circulating Tumor Cells -- Detection of CTCs by RT-PCR -- CTC Enrichment Technologies -- Enrichment by Physical Properties -- Cell Surface Marker-Based Enrichment -- Emerging Technologies -- Microfluidic Devices -- High-Definition CTC -- DEParray -- Positive Versus Negative Enrichment of CTCs -- Quantification of CTCs as a Predictor of Survival and a Marker of Therapy Response -- CTC Characterization and Monitoring Therapy Responses -- Concluding Remarks -- Summary Points -- References -- 3 Oncoproteomic Approaches to Cancer Marker Discovery: The Case of Colorectal Cancer -- Key Facts -- Definition of Words and Terms -- Introduction -- Colorectal Cancer -- Biomarkers in Cancer -- Why Proteomics? -- Proteomic Technologies -- Two-Dimensional Gel Electrophoresis -- Gel-Free Proteomics: Isotopic Labeling -- Label-Free Mass Spectrometry -- Detection of Post-Translational Modifications -- Early Detection Screening Technologies and Samples for CRC Biomarker Research.
Protein Biomarkers of Colon Cancer -- Carcinoembryonic Antigen -- Fecal Hemoglobin -- Potential Application of Proteomics to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 4 Cancer Cardiotoxicity and Cardiac Biomarkers -- Definition of Words and Terms -- Introduction -- Cardiotoxicity of Cancer Therapy -- Summary Points -- Key Facts of Cardiotoxicity -- Chemotherapeutic Agents -- Anthracycline -- Targeted Therapy -- Trastuzumab -- Inhibitors of Angiogenesis -- Summary Points -- Key Facts of Chemotherapeutic Agents -- Monitoring of Drug-Induced Cardiotoxicity -- Cardiac Imaging -- Serological Markers -- Summary Points -- Key Facts of Monitoring of Drug-Induced Cardiotoxicity -- Troponins -- Summary Points -- Key Facts of Troponin -- Natriuretic Peptides -- Summary Points -- Key Facts of Natriuretic Peptide -- Potential Application to Prognosis and Other Disease Conditions -- Summary Points -- Key Facts of Potential Application to Prognosis and Other Disease Conditions -- References -- 5 DNA Methylation as a Biomarker in Cancer -- Key Facts -- Key Facts of DNMT: DNA Methyltransferase -- Key Facts of CGIs: CpG Islands -- Key Facts of MBD Proteins: Methyl-CpG-Binding-Domain Proteins -- Definitions of Words and Terms -- Introduction -- DNA Methylation in Normal Cells -- Relationship Between CGI DNA Methylation and Transcriptional Repression -- DNA Methylation in Cancer Cells -- 5-Hydroxymethylcytosine and Its Derivatives in Cancer -- Long-Range Coordinated Disruptions in DNA Methylation -- CpG Island Methylator Phenotype -- Methods of Isolating DNA Methylation Biomarkers in Cancer -- DNA Methylation Changes in Early Tumorigenesis -- The Suitability of DNA Methylation Changes as Biomarkers -- DNA Methylation as Early Detection Biomarkers -- DNA Methylation Biomarkers for Prediction of Drug Sensitivity -- Future Perspectives. Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 6 Kallikreins as Biomarkers in Human Malignancies -- Key Facts on Kallikrein Family -- Definitions of Words and Terms -- Introduction -- KLK Family: A Rich Source of Cancer Biomarkers -- Prostate Cancer -- Prostate-Specific Antigen (PSA/KLK3): A Long-Used yet Disputed Biomarker for CaP Screening and Diagnosis -- PSA/KLK3: Applications in CaP Patients´ Treatment Monitoring and Prediction of Clinical Outcome -- Emerging Biomarkers in Prostate Cancer from the Kallikrein Family: Can They Follow and/or Enrich the Success of PSA/KLK3? -- Diagnostic Significance -- Prostate Cancer Prognosis -- Ovarian Cancer -- KLK6, KLK10, and Other KLK Family Members as Promising Markers in Ovarian Cancer Diagnosis -- KLKs with Potential Prognostic and/or Predictive Value in Ovarian Cancer -- Breast Cancer -- KLKs with Diagnostic Significance for Breast Cancer -- Prognosis and Treatment Monitoring -- Endometrial and Cervical Cancer -- KLKs with Potential Clinical Utility in Endometrial Carcinomas -- KLKs with Potential Clinical Utility in Cervical Cancer -- Renal Cell Carcinoma and Urinary Bladder Cancer -- KLKs with Potential Clinical Utility in RCC and Bladder Cancer -- Gastric and Colon Cancer -- KLKs with Potential Clinical Utility in Gastric Cancer -- KLKs with Potential Clinical Utility in Colon Cancer -- Other Types of Human Cancer -- KLK-Targeting MicroRNAs: A New Era in Cancer Research Has Just Begun -- Single-Nucleotide Polymorphisms (SNPs) in the Human KLK Locus -- Methodologies and Analytical Techniques -- Potential Applications of KLK Family Members to Prognosis, Nonmalignant Diseases, or Conditions -- KLKs and CNS Disorders -- KLKs in Skin Disorders -- Conclusions -- Summary Points -- References -- 7 MAP17 as Biomarker for Cancer Treatment -- Key Facts. Definitions of Words and Terms -- Introduction -- MAP17 (PDZK1IP1) -- MAP17 in Human Tumors -- Oncogenic Activity of MAP17 -- Potential Applications to Prognosis, Diagnosis, or Response to Therapy -- Summary Points -- References -- 8 CA 19-9 as a Serum Biomarker in Cancer -- Definitions of Words and Terms -- Introduction -- CA 19-9 Measurement Methodology -- CA 19-9 and Its Utility in Pancreatic Cancer -- Epidemiology of Pancreas Cancer -- CA 19-9 Level as a Diagnostic Marker/Screening Tool in Pancreatic Cancer -- CA 19-9 Level as a Prognostic Marker in Resectable Pancreatic Adenocarcinoma -- CA 19-9 Level as a Prognostic Marker in Advanced and Metastatic Pancreatic Adenocarcinoma -- CA 19-9 in Intraductal Papillary Mucinous Neoplasms of the Pancreas -- CA 19-9 in Gastric Cancer -- CA 19-9 in Biliary Tract Cancers -- CA 19-9 in Colorectal Cancer -- CA 19-9 in Ovarian Cancer -- Utility in Other Malignancies -- CA 19-9 in Occult Primary -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 9 PTTG (Securin) as Cancer Biomarker -- Key Facts of Pituitary Gland -- Definitions of Words and Terms -- Introduction -- Discovery of the Pituitary Tumor Transforming Gene -- PTTG in Cancer -- PTTG Is an Oncogene -- Basic Molecular PTTG Functions in Cancer not Restricted to Pituitary Adenomas -- Role in Genetic Instability -- Role as a Broad Regulator of the Transcriptome -- Motility, Invasion, and Metastasis -- Epidermal to Mesenchymal Transition -- Clinical Impact of PTTG -- PTTG as a Prognostic Marker -- Cellular Proliferation -- Vascular Proliferation -- Migratory Ability of Tumor Cells -- Perspectives for a Prognostic Application of PTTG in Clinical Practice -- Therapeutic Aspects -- Concluding Remarks -- Summary Points -- References -- 10 U2 Small Nuclear RNA as a Biomarker in Cancer. Key Facts of Noncoding RNAs as Biomarkers -- Definition of Words and Terms -- Introduction -- U2 snRNA and the Splicing Process of Pre-mRNAs -- Genomic Organization and Sequence Characteristics of U2 snRNA -- RNU2-1 Fragment Biogenesis and Stability -- RNU2-1f in Serum of Pancreatic and Colorectal Cancer Patients -- RNU2-1f in Lung Cancer -- RNU2-1f as Biomarker in Other Cancer Types -- Potential Applications of RNU2-1f Tests to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- Part II: Bladder, Kidney, Liver and Lung -- 11 Centrosome Amplification as Biomarkers in Bladder Cancer Using Touch Biopsy and Bladder Washing Cytological Specimens -- Key Facts of Centrosome Amplification -- Definitions of Words and Terms -- Introduction -- Mechanism of Centrosome Amplification -- Copy Number Aberrations and Centrosome Amplification -- Clinical Significance of Centrosome Amplification -- Other Biomarkers Using Urine (Bladder Washing Cytology) -- Potential Applications to Prognosis -- Conclusion -- Summary Points -- References -- 12 Microarrays and Renal Cell Cancer Biomarkers -- Key Facts of Renal Cell Carcinoma -- Definitions of Words and Terms -- Introduction -- Genomic Approaches -- Array-Based CGH (aCGH) and SNP Arrays for Tracking Potential Chromosomal and Gene Marker Loci -- DNA Methylation Arrays for Unmasking Silenced RCC Markers -- Transcriptomic Approaches -- DNA Microarrays for Screening RCC-Specific Marker Expression Patterns -- miRNA Microarrays for Identifying RCC Key Players of Gene Regulation -- Proteomic Approaches -- Tissue Microarrays (TMA) for Evaluating Molecular Markers with Clinical Relevance in RCC -- Combinations of Microarray Platforms Used to Validate Potential Biomarkers in RCC -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References. 13 Immunogenic Cell Death Markers in Liver Cancer. |
| Record Nr. | UNINA-9910298270203321 |
| Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Diagnosis : Tumor Immunodiagnostic Tests / / edited by Nima Rezaei
| Cancer Diagnosis : Tumor Immunodiagnostic Tests / / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (1162 pages) |
| Disciplina | 616.9940756 |
| Collana | Handbook of Cancer and Immunology |
| Soggetto topico |
Cancer
Immunology Immunotherapy Tumors - Immunological aspects Cancer - Treatment Cancer Biology Tumour Immunology Cancer Therapy |
| ISBN | 3-032-00763-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction on Cancer Immunodiagnosis -- Immunodiagnostics A Perspective on Sensitivity, Specificity, and Stability of Tumor Antigens -- Immunohistochemistry and Molecular Biology of Cancer -- Immunohistochemistry in the Diagnosis of Primary and Secondary Cancers -- Biomarkers for Monitoring the Immunotherapy Response to Cancer -- Predictive and On Treatment Monitoring Role of Circulating Biomarkers in Immuno-oncology -- Autoantibodies as Diagnostic Cancer Biomarkers -- Proteomics and Protein Biomarkers in Cancer Metastasis -- Role of Cyclin-Dependent Kinase Inhibitors (CKIs) as a Prognostic Biomarker for Cancer -- Single-Cell Sequencing in Cancer Research Challenges and Opportunities. |
| Record Nr. | UNINA-9911031632603321 |
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||